Welcome to the RYBELSUS® (semaglutide tablets) UK microsite

This website has been developed by Novo Nordisk UK and contains product and prescribing information about RYBELSUS® intended for UK healthcare professionals. In addition, the site contains specific information for patients prescribed RYBELSUS® and general information for the public. 

 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard↗. By reporting side effects you can help to provide more information on the safety of this medicine.

Please select the appropriate option below to continue:

What’s your medical profession?


So that we can serve you the content that matters to you, please share your medical role with us. This information will not be used in any other way, but to maximise your experience on this website.